hamburger-icon
close-icon

invest-iconInvest

trade-iconTrade

depository-iconTrading Platforms

depository-iconDepository

watch-iconWatch Markets

depository-iconFPI

watch-iconMerchant Banking

watch-iconInstitutional Broking

watch-iconPMS

watch-iconPre-IPO

watch-iconStock Market Institute – AIFE

watch-iconMTF

partner-iconBecome a Partner

partner-iconKnowledge Center

watch-iconResearch

support-iconWealth Basket

about-iconAbout Us

support-iconSupport

support-iconPricing

support-iconQuick Links

support-iconBlog

support-iconAlgo Trading

hamburger-icon
close-icon

Glenmark Pharmaceuticals Ltd

  • BSE Code : 532296
  • NSE Symbol : GLENMARK
  • ISIN : INE935A01035
  • Industry :PHARMACEUTICALS - INDIAN - BULK DRUGS & FORMLN
Trade Now

up-arrow 2,091.80 -9.30(-0.44%)

Open Price (₹)

2,085.00

Prev. Close (₹)

2,101.10

Volume (No’s)

970,078

Market Cap (₹)

59,030.77

Low Price (₹)

1,966.50

High Price (₹)

2,098.40

 

Board Meetings

Start Date End Date Purpose
19-Jan-2026 30-Jan-2026 Quarterly Results Glenmark Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2026 ,inter alia, to consider and approve the Unaudited Financial Results of the Company for the Third Quarter and Nine Months ended December 31, 2025. Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Board at its meeting held today has approved the unaudited financial results for the Third Quarter and Nine Months ended 31st December, 2025 (As Per BSE Announcement Dated On : 30.01.2026)
03-Nov-2025 14-Nov-2025 Glenmark Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 inter alia to consider and approve the Unaudited Financial Results of the Company for the second quarter and half year ended September 30 2025 Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Board at its meeting held today has approved the unaudited financial results for the Second Quarter and Half Year ended 30th September, 2025. (As Per BSE Announcement Dated on 14.11.2025)
22-Sep-2025 26-Sep-2025 Glenmark Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/09/2025 inter alia to consider and approve payment of interim dividend if any on Equity Shares of the Company for the financial year 2025-26. Outcome Of The Board Meeting Held On 26Th September, 2025 The Board approved Interim Dividend of Rs. 2.50 per equity shares on face value of Re. 1/- per equity shares for the Financial Year 2025-26 and reconstitution of Committees. (As Per BSE Announcement Dated on 26.09.2025)
04-Aug-2025 14-Aug-2025 Glenmark Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2025 inter alia to consider and approve the Unaudited Financial Results of the Company for the First Quarter ended June 30 2025. Please find attached herewith Unaudited Financial Results for the first quarter ended 30th June, 2025 (As Per BSE Announcement Dated on: 14.08.2025)
12-May-2025 23-May-2025 Glenmark Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2025 inter alia to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and year ended March 31 2025 and to consider and recommend dividend if any on Equity shares for the year ended March 31 2025. The Board of Directors of Glenmark Pharmaceuticals Limited at its meeting held on 23rd May, 2025, which commenced at 02.00 p.m. and concluded at 04:54 p.m., considered and approved the following: 1. Audited Financial Results for the quarter and year ended March 31, 2025. Pursuant to regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, find enclosed herewith the said results together with Auditors Report and Declaration of unmodified opinion. These are also being made available on the website of the Company at www.glenmarkpharma.com. 2. Recommended Dividend @ 250% i.e. Rs. 2.5/- per share (face value of Re. 1/- each) on the Equity Share Capital of the Company for the financial year 2024-25 subject to the approval of the Shareholders at the ensuing Annual General Meeting. (As Per BSE Announcement Dated on: 23/05/2025)

NIFTY:22,713.10  Up arrow
33.70(0.15%)
SENSEX:73,134.32  Up arrow
185.23(0.25%)

Product

Trading


Useful links

Who we are

Connect with us

Stay on top of the markets with our bite-sized newsletter delivered right to your Inbox!

footer-arrow-icon
appstore appstore

#1011 Solitaire Corporate Park, Andheri Ghatkopar Link Road, Chakala, Andheri (E), Mumbai - 400093.

Arihant Capital Markets Limited is a SEBI registered stock broker and depository participant. SEBI Registration number: INZ000180939, Member of NSE:07839; BSE :313; NSDL - IN-DP-127-2015 DP ID-IN301983; CDSL DP ID-43000; NCDEX - 01274; MCX - 56565; AMFI - ARN 15114; AMFI-registered Mutual Fund Distributor; ARN registration year - 2004; ARN validity up to- 18/12/2028; SEBI Merchant Banking Reg. No. - MB INM000011070; SEBI Research Analyst Reg. No. - INH000002764 (BSE RA Enlistment No. 5168) . Registered Address: 601, Atlantis Tower, Plot No. 13 A, Scheme N0. 78, Indore 452010 (MP). Corporate office address: #1011 Solitaire Corporate Park, Andheri Ghatkopar Link Road, Chakala, Andheri (E), Mumbai - 400093. CIN: L66120MP1992PLC007182.

APMI Distributor Registration Name of Distributor : Arihant Capital Markets limited Enrollment Date : 26/03/2025 APRN Code : APRN04950 APRN code is valid from 06/01/2025 till 05/01/2028.

Please carefully read the risk disclosure document as prescribed by SEBI, as well as the 'Do’s and Don’ts' provided by NSE, BSE, NCDEX, and MCX. If you have any complaints related to securities broking, kindly contact us at complaint@arihantcapital.com. For DP-related matters, please reach out to us at depository@arihantcapital.com.

If you want to register your complaints through SEBI Score 2.0 Portal please click here. Mandatory details for filing complaints on SCORES: Name, PAN, Address, Mobile Number, E-mail ID. Benefits: Effective Communication, Speedy redressal of the grievances

Investments in securities market are subject to market risks; read all the related documents carefully before investing.

Disclaimer: Arihant Capital Markets Limited is engaged in client based and proprietary trading on various exchanges.

  • ATTENTION INVESTORS :
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (Broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • For Stock Broking Transaction 'Prevent unauthorised transactions in your account - update your mobile numbers/email IDs with your stockbrokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day.
  • For Depository Transaction 'Prevent Unauthorized Transactions in your demat account - Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL/NSDL on the same day.
  • If you are subscribing to an IPO, there is no need to issue cheques. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
  • Investors should be cautious on unsolicited emails and SMS advising to buy, sell or hold securities and trade only on the basis of informed decision. Investors are advised to invest after conducting appropriate analysis of respective companies and not to blindly follow unfounded rumours, tips etc. Further, you are also requested to share your knowledge or evidence of systemic wrongdoing, potential frauds or unethical behaviour through the anonymous portal facility provided on BSE & NSE website.
  • Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
  • Pay 20% or "var + elm" whichever is higher as upfront margin of the transaction value to trade in cash market segment.
  • Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.

  • Risk disclosures on Derivatives:
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost

  • Advisory - Investors :
  • Ensure that pay-out of funds/securities is received in your account within 1 working day from the date of pay-out.
  • Register for online applications viz Speed-e and Easiest provided by Depositories for online delivery of securities as an alternative to DDPI/POA.
  • Ensure that you receive Contract Notes within 24 hours of your trades and Statement of Account at least once in a quarter from your Stock Broker.
  • If you have opted for running account, please ensure that the stock broker settles your account regularly and in any case not later than 90 days (or 30 days if you have opted for 30 days settlement).
  • Do not keep funds idle with the Stock Broker.
  • Regularly login into your account to verify balances and verify the demat statement received from depositories for correctness.
  • Check messages sent by Exchanges on a monthly basis regarding funds and securities balances reported by the trading member and immediately raise a concern if you notice a discrepancy.
  • Always keep your contact details viz Mobile number / Email ID updated with the stock broker. You may take up the matter with Stock Broker / Exchange if you are not receiving the messages from Exchange / Depositories regularly.
  • If you observe any discrepancies in your account or settlements, immediately take up the same with your stock broker and if the Stock Broker does not respond, with the Exchange/Depositories.
  • Beware of fixed/guaranteed/regular returns/ capital protection schemes. Brokers or their authorized persons or any of their associates are not authorized to offer fixed/guaranteed/regular returns/ capital protection on your investment or authorized to enter into any loan agreement with you to pay interest on the funds offered by you. Please note that in case of default of a member claim for funds or securities given to the broker under any arrangement/ agreement of indicative return will not be accepted by the relevant Committee of the Exchange as per the approved norms.
  • Please do not transfer funds, for the purposes of trading to anyone, including an authorized person or an associate of the broker, other than a SEBI registered Stock broker.

  • As per advisory issued by exchanges, while dealing in options, clients/investors shall avoid the following:
  • Sharing of trading credentials – login id & passwords including OTP’s.
  • Trading in leveraged products like options without proper understanding, which could lead to losses.
  • Writing/ selling options or trading in option strategies based on tips, without basic knowledge & understanding of the product and its risks.
  • Dealing in unsolicited tips through WhatsApp, Telegram, YouTube, Facebook, SMS, calls, etc.
  • Trading in “Options” based on recommendations from unauthorized / unregistered investment advisors and influencers.

Awareness regarding guidelines of margin collection:
1)Stock brokers can accept securities as margins from clients only by way of pledge in the depository system w.e.f September 01, 2020.
2)Update your e-mail and phone number with your stock broker / depository participant and receive OTP directly from depository on your e-mail and/or mobile number to create pledge.
3)Check your securities / MF / bonds in the consolidated account statement issued by NSDL/CDSL every month.
Issued in the interest of investors

Dear Investor - As you are aware, under the rapidly evolving dynamics of financial markets, it is crucial for investors to remain updated and well-informed about various aspects of investing in securities market. In this connection, please find a link to the BSE Investor Protection Fund website where you will find some useful educative material in the form of text and videos, so as to become an informed investor. https://www.bseipf.com/investors_education.html

Copyright © 2026 Arihant Capital Markets Ltd. All rights Reserved.

Designed, Developed and Content powered by CMOTS InfoTech (ISO 9001:2015 & ISO/IEC 27001:2022 Certified)

x
  • QR-CodeNew